188 related articles for article (PubMed ID: 24837491)
1. Hsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer.
Leung YK; Chan QK; Ng CF; Ma FM; Tse HM; To KF; Maranchie J; Ho SM; Lau KM
PLoS One; 2014; 9(5):e98037. PubMed ID: 24837491
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.
Rao X; Di Leva G; Li M; Fang F; Devlin C; Hartman-Frey C; Burow ME; Ivan M; Croce CM; Nephew KP
Oncogene; 2011 Mar; 30(9):1082-97. PubMed ID: 21057537
[TBL] [Abstract][Full Text] [Related]
3. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
Li Z; Zhu Q; Chen H; Hu L; Negi H; Zheng Y; Ahmed Y; Wu Z; Li D
Cancer Lett; 2016 Jul; 377(1):32-43. PubMed ID: 27063095
[TBL] [Abstract][Full Text] [Related]
4. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
5. Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.
Montgomery B; Nelson PS; Vessella R; Kalhorn T; Hess D; Corey E
BMC Cancer; 2010 May; 10():244. PubMed ID: 20509933
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant-mediated inhibition of estrogen receptor signaling slows lung cancer progression.
Tang H; Liao Y; Zhang C; Chen G; Xu L; Liu Z; Fu S; Yu L; Zhou S
Oncol Res; 2014; 22(1):13-20. PubMed ID: 25700354
[TBL] [Abstract][Full Text] [Related]
7. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.
Agrawal A; Robertson JF; Cheung KL; Gutteridge E; Ellis IO; Nicholson RI; Gee JM
Int J Cancer; 2016 Jan; 138(1):146-59. PubMed ID: 26178788
[TBL] [Abstract][Full Text] [Related]
8. Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma.
Song W; He D; Chen Y; Yeh CR; Hsu I; Huang Q; Zhang X; Chang LS; Zuo L; Chen J; Doersch KM; Chang C; Li L; Yeh S
Mol Oncol; 2018 Dec; 12(12):2055-2071. PubMed ID: 30171816
[TBL] [Abstract][Full Text] [Related]
9. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
10. Targeting Toll-like receptor 4 with CLI-095 (TAK-242) enhances the antimetastatic effect of the estrogen receptor antagonist fulvestrant on non-small cell lung cancer.
Fan S; Liao Y; Qiu W; Li L; Li D; Cao X; Ai B
Clin Transl Oncol; 2020 Nov; 22(11):2074-2086. PubMed ID: 32367494
[TBL] [Abstract][Full Text] [Related]
11. Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells.
Maggiolini M; Recchia AG; Carpino A; Vivacqua A; Fasanella G; Rago V; Pezzi V; Briand PA; Picard D; Andò S
J Mol Endocrinol; 2004 Jun; 32(3):777-91. PubMed ID: 15171712
[TBL] [Abstract][Full Text] [Related]
12. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X
Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813
[TBL] [Abstract][Full Text] [Related]
13. hsa_circ_0062019 promotes the proliferation, migration, and invasion of prostate cancer cells via the miR-195-5p/HMGA2 axis.
Wang P; Zhang L; Yin S; Xu Y; Tai S; Zhang LI; Liang C
Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(7):815-822. PubMed ID: 33978716
[TBL] [Abstract][Full Text] [Related]
14. Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERβ and KLF5.
Nakajima Y; Akaogi K; Suzuki T; Osakabe A; Yamaguchi C; Sunahara N; Ishida J; Kako K; Ogawa S; Fujimura T; Homma Y; Fukamizu A; Murayama A; Kimura K; Inoue S; Yanagisawa J
Sci Signal; 2011 Apr; 4(168):ra22. PubMed ID: 21487105
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Bhattacharyya RS; Krishnan AV; Swami S; Feldman D
Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
[TBL] [Abstract][Full Text] [Related]
16. Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.
Poggio F; Lambertini M; Blondeaux E; Vaglica M; Levaggi A; Pronzato P; Del Mastro L
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1153-61. PubMed ID: 27545815
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1.
Rajendiran S; Parwani AV; Hare RJ; Dasgupta S; Roby RK; Vishwanatha JK
Mol Cancer; 2014 Nov; 13():250. PubMed ID: 25406943
[TBL] [Abstract][Full Text] [Related]
18. Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis.
Budd WT; Seashols-Williams SJ; Clark GC; Weaver D; Calvert V; Petricoin E; Dragoescu EA; O'Hanlon K; Zehner ZE
PLoS One; 2015; 10(11):e0142373. PubMed ID: 26544868
[TBL] [Abstract][Full Text] [Related]
19. Estradiol regulates miR-135b and mismatch repair gene expressions via estrogen receptor-β in colorectal cells.
He YQ; Sheng JQ; Ling XL; Fu L; Jin P; Yen L; Rao J
Exp Mol Med; 2012 Dec; 44(12):723-32. PubMed ID: 23143558
[TBL] [Abstract][Full Text] [Related]
20. The CircRNA-ACAP2/Hsa-miR-21-5p/ Tiam1 Regulatory Feedback Circuit Affects the Proliferation, Migration, and Invasion of Colon Cancer SW480 Cells.
He JH; Li YG; Han ZP; Zhou JB; Chen WM; Lv YB; He ML; Zuo JD; Zheng L
Cell Physiol Biochem; 2018; 49(4):1539-1550. PubMed ID: 30212824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
